BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26791373)

  • 1. PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection?
    Chiaravalloti A; Di Biagio D; Tavolozza M; Calabria F; Schillaci O
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1418-24. PubMed ID: 26791373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy.
    Schillaci O; Calabria F; Tavolozza M; Caracciolo CR; Finazzi Agrò E; Miano R; Orlacchio A; Danieli R; Simonetti G
    Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):589-96. PubMed ID: 22231016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
    Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
    Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
    Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.
    Marzola MC; Chondrogiannis S; Ferretti A; Grassetto G; Rampin L; Massaro A; Castellucci P; Picchio M; Al-Nahhas A; Colletti PM; Marcolongo A; Rubello D
    Clin Nucl Med; 2013 Jan; 38(1):e26-32. PubMed ID: 23242060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
    Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
    Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
    J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.
    Ceci F; Castellucci P; Mamede M; Schiavina R; Rubello D; Fuccio C; Ambrosini V; Boschi S; Martorana G; Fanti S
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):149-55. PubMed ID: 23151910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of PET-CT with
    Puche-Sanz I; Triviño-Ibáñez E; Vázquez-Alonso F; Llamas-Elvira JM; Cózar-Olmo JM; Rodríguez-Fernández A
    Actas Urol Esp; 2017 Sep; 41(7):437-444. PubMed ID: 28389027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Scattoni V; Garcia Parra R; Briganti A; Gianolli L; Montorsi F; Messa C
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1106-16. PubMed ID: 20306038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic performance of
    Samper Ots P; Luis Cardo A; Vallejo Ocaña C; Cabeza Rodríguez MA; Glaria Enríquez LA; Couselo Paniagua ML; Olivera Vegas J
    Clin Transl Oncol; 2019 Jun; 21(6):766-773. PubMed ID: 30448957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
    J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen kinetics parameters are predictive of positron emission tomography features worsening in patients with biochemical relapse after prostate cancer treatment with radical intent: Results from a longitudinal cohort study.
    Gacci M; Cai T; Siena G; Minervini A; Torshizi MF; Bartolini M; Giannì G; Saieva C; Ceroti M; Detti B; Livi L; Pupi A; Carini M
    Scand J Urol; 2014 Jun; 48(3):259-67. PubMed ID: 24255954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of 18F-fluorocoline PET/CT in prostate cancer patients with biochemical recurrence: Influence of PSA kinetics and hormone therapy.
    Triviño-Ibáñez EM; Puche-Sanz I; Gómez-Río M; Cózar Olmo JM; Llamas-Elvira JM; Rodríguez-Fernández A
    Med Clin (Barc); 2019 Jul; 153(2):56-62. PubMed ID: 30660434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?
    Heinisch M; Dirisamer A; Loidl W; Stoiber F; Gruy B; Haim S; Langsteger W
    Mol Imaging Biol; 2006; 8(1):43-8. PubMed ID: 16315004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of fluorine-18-fluoromethylcholine PET/CT to prostate-specific antigen over different plasma levels: a retrospective study in a cohort of 192 patients with prostate cancer.
    Giovacchini G; Giovannini E; Borsò E; Lazzeri P; Riondato M; Leoncini R; Duce V; Conti E; Picchio M; Ciarmiello A
    Nucl Med Commun; 2019 Mar; 40(3):258-263. PubMed ID: 30507748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis.
    Treglia G; Ceriani L; Sadeghi R; Giovacchini G; Giovanella L
    Clin Chem Lab Med; 2014 May; 52(5):725-33. PubMed ID: 24310773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Liu C; Zhu Y; Su H; Xu X; Zhang Y; Ye D; Hu S
    Prostate; 2018 Dec; 78(16):1215-1221. PubMed ID: 30027591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.